Drug Fix: Oncology Stalwart Richard Pazdur Leaves US FDA
PreVision Policy Founding Member Michael McCaughan joins Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter and Editor-in-Chief Nie...
Building a Nasal First line of Defense Against H5N1
Intranasal vaccines are back in the spotlight as highly pathogenic avian influenza spreads among birds and spills over into mammals, including recent ...
Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast)
本期播客内容来自《Scrip》杂志，精选内容涵盖截至2025年12月19日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻——再生元夹在成功与专利到期之间；第三季度十大畅销药物；礼来Retatrutide重塑减重标准；辉瑞坚守疫苗投资；赛诺菲在托布替尼困境...
Scrip's Five Must-Know Things - Dec. 22, 2025
Audio roundup of selected biopharma industry content from Scrip over the business week ended December 19, 2025. This episode was produced with the hel...
“We Are On The Cusp Of A Real Revolution”: OHC Rare Disease Center Boosts Innovation
Matthew Wood, director and chief scientific officer at Oxford-Harrington Rare Disease Center, discusses the state of rare disease R&D, the evolving la...
Scrip Awards Podcast, 2025 Winners
This podcast brings you highlights from Scrip Awards 2025, including wins for AstraZeneca, Syndax, Akeso and Summit Therapeutics and the Lifetime Achi...
Datamonitor Healthcare Podcast: A Deep Dive into Dry AMD
Emma Wille and Summer Colling speak with ophthalmology expert, Joseph Jacob, to discuss the latest developments in dry age-related macular degeneratio...
Scrip M&A Podcast: PwC's Dealmaking Preview for 2026
Scrip senior writer Joseph Haas and PwC analyst Roel Van den Akker look back on biopharma sector dealmaking in 2025, why deal values rose from 2024's ...
Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast)
本期播客内容来自《Scrip》杂志，精选内容涵盖截至2025年12月12日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期聚焦美国血液学会（ASH）会议五大关键成果：Jaypirca有望成为一线疗法；Kite公司Anito-cel在多发性骨髓瘤领域的进展；新一...
Scrip's Five Must-Know Things - Dec. 15, 2025
Audio roundup of selected biopharma industry content from Scrip over the business week ended December 12, 2025. This week, a focus on five key results...